首页> 外文期刊>The European journal of health economics: HEPAC : health economics in prevention and care >Price-cost margin in the pharmaceutical industry: Empirical evidence from Finland
【24h】

Price-cost margin in the pharmaceutical industry: Empirical evidence from Finland

机译:制药业的价格成本利润率:芬兰的经验证据

获取原文
获取原文并翻译 | 示例
       

摘要

This contribution estimates the price-cost margin in the Finnish pharmaceutical industry. The estimation is based on the method developed by Hall who shows that under constant returns to scale total factor productivity growth depends on the growth of output-capital ratio if the market is imperfectly competitive. Measurement of the price-cost margin is based on this theoretical result. We utilize data on the Finnish pharmaceutical industry. The data cover the years 1975–1999 and include information on output, labor hours, and capital stock. The results show that the estimated price-cost margin is in the range 0.59–0.67, which is close to the estimates obtained in the United States market.
机译:这一贡献估计了芬兰制药业的价格成本利润率。该估计基于Hall提出的方法,该方法表明,在规模不变的收益下,如果市场竞争不完全,那么全要素生产率的增长取决于产出资本比的增长。价格-成本边际的度量基于此理论结果。我们利用芬兰制药业的数据。数据涵盖了1975-1999年,并包括有关产出,劳动时间和资本存量的信息。结果表明,估计的价格成本利润率在0.59–0.67的范围内,与在美国市场上获得的估计值相近。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号